FDC Limited

BSE: 531599 NSE: FDC
FDC Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24239MH1940PLC003176 Incorporated 23 September 1940 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: FDC · BSE: 531599 Public Limited Company pharma
Data last updated
Market Cap
₹6,392 Cr
FDC · NSE
Share Price
₹394.20
+0.41% today
Revenue
₹2,171 Cr
FY 2025-26 · +3.0% YoY
EBITDA
₹325 Cr
Margin 15.0%
Net Profit
₹268 Cr
FY 2025-26 · +5.5% YoY
P/E (TTM)
19.3x
P/B 2.4x
ROE
11.8%
ROCE 15.6%
Debt / Equity
0.01
Interest cover 1.9x

About FDC Limited

Data last updated:

FDC Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 September 1940 and has been in existence for over 86 years.

Its director Mohan Anand Chandavarkar and family are #1,374 among India's richest people (2026). Its director Ashok Anand Chandavarkar and family are #1,750 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24239MH1940PLC003176. The company has 2 GST registrations on record, none of which is active. It is a listed company as per MCA records. Its shares are listed on BSE: 531599 and NSE: FDC.

The company has an authorised share capital of ₹29.45 Cr and a paid-up capital of ₹16.28 Cr. It was formerly known as Fairdeal Corporation Private Limited and The Fairdeal Corporation Pvt Ltd. It is led by directors including Mohan Chandavarkar Anand (Managing Director) and Nandan Mohan Chandavarkar (Whole-Time Director).

Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,170.93 Cr, a growth of 3% compared to the previous year. For the same year it recorded a net profit of ₹267.72 Cr (net margin 12.3%) and EBITDA of ₹325.31 Cr (EBITDA margin 15%). The net worth stands at ₹2,485.11 Cr (up 8.9% YoY). Total assets are valued at ₹2,529.04 Cr (up 8.2% YoY).

The company has about 6,548 employees on its provident fund (EPFO) records.

The company is associated with 5 brands: Pixel Eye Care, Enerzal, FDC Limited, ZiFi and Zifi. As per MCA filings, the company has satisfied charges of ₹7.43 Cr on record. Court records list 333 cases involving the company, including 200 filed by the company and 133 filed against it; 58 cases are pending. The company has 29 deals on record (18 secondary share transfers, 9 market trades, 2 buybacks); the latest was in September 2024. Its 5 peer companies in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 2 larger and 3 smaller; the largest is Pfizer Limited with revenue of ₹2,453.6 Cr. The company has 16 MSME Form 1 returns on record between 2017 and 2022, listing 1,308 overdue payments to 330 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fdcindia.com.

Company details

CIN L24239MH1940PLC003176
Registration Number 003176
Incorporation Date 23 September 1940
ROC Mumbai
Listing Status Listed - Listed on NSE (FDC); Listed on BSE (531599)
Company Status Active
Date of Last AGM 25 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

FDC has undergone 2 name changes throughout its history. The company was previously known as Fairdeal Corporation Private Limited, and The Fairdeal Corporation Pvt Ltd. The current legal name is Fdc Limited.

Company NameStatus
FDC LimitedCurrent
Fairdeal Corporation Private LimitedPrevious
The Fairdeal Corporation Pvt LtdPrevious

CIN history

FDC has one previous CIN (Corporate Identification Number): U24239MH1940PLC003176. The current CIN is L24239MH1940PLC003176, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239MH1940PLC003176Current
U24239MH1940PLC003176Previous
Key People
Mohan Chandavarkar Anand Managing Director Nandan Mohan Chandavarkar Whole-Time Director Ashok Anand Chandavarkar Whole-Time Director

Recognitions & Rankings of FDC

India's Most Valuable Companies 2021 edition · Source: Hurun India
Rank#496
Valuation
₹5,688 Cr

Contact details

FDC Limited's registered office is in Mumbai, Maharashtra. Its website is fdcindia.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    fdcindia.com
  • Social Media
  • Registered Address
    Fdc House C – 11 & 12 Dalia Industrial Estate, Oshiwara Village Off New Link Road Andheri (West), Mumbai, Maharashtra, India – 400053
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of FDC Limited, buy the company report.

Comprehensive company report
FDC Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

FDC operates multiple associated brands including Pixel Eye Care, Enerzal, and FDC Limited. Each brand links to its own profile.

BrandDescriptionWebsite
Pixel Eye Care
Delivers a comprehensive app for telemedicine services with ophthalmologists.pixeleyecare.com
Enerzal
Provides powdered and liquid energy drinks to refuel, replenish, and rehydrate users.enerzal.com
FDC Limited
Pharmaceuticals and consumer healthcare products are manufactured and exported.fdcindia.com
ZiFi
Accounting, invoicing, and banking solutions for individuals and businesseszifi.com
Zifi
Therapeutics for bacterial infections are developed by Zifi.zifi.co.in

Business activity

The main business activity of FDC is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of FDC Limited, buy the company report.

Financials of FDC Limited

FY 2025-26 filings available

FDC Limited reported revenue of ₹2,170.93 Cr (up 3% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,171 Cr
+3.0% YoY
EBITDA
₹325 Cr
+0.2% YoY
Profit After Tax
₹268 Cr
+5.5% YoY
Net Worth
₹2,485 Cr
+8.9% YoY
Total Assets
₹2,529 Cr
+8.2% YoY
Total Debt
₹15.47 Cr
-26.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1712,1081,9431,7841,5281,3331,344
Revenue growth+3.0%+8.5%+8.9%+16.7%+14.6%-0.8%-
EBITDA325325339251254332292
EBITDA margin+15.0%+15.4%+17.4%+14.1%+16.6%+24.9%+21.7%
Profit before tax375357396258289388320
Net profit268254289190211284236
Net profit margin+12.3%+12.0%+14.9%+10.6%+13.8%+21.3%+17.5%
EPS (₹)17.2916.3918.7511.7012.8217.8514.03
Balance sheet
Total assets2,5292,3382,1482,0281,9891,7491,563
Net worth2,4852,2812,0971,9821,9571,7341,547
Total debt15.4721.1720.5228.3232.2014.5415.08
Cash & bank50.0052.7726.2924.9438.6631.5832.32
Net working capital301251314266234212184
Cash flow
Cash from operations200318221155162207250
Cash from investing(110)(199)(17.08)11.20(145)(77.18)(98.42)
Cash from financing(93.33)(92.12)(202)(180)(9.84)(129)(142)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue572668585465473648492464
Revenue growth (YoY)+21.0%+3.0%+18.9%+0.1%-7.9%+1.6%--
Other income17.9447.6649.8920.8020.6335.5016.0818.83
EBITDA64.2914310631.4933.8114053.9846.65
EBITDA margin+11.2%+21.4%+18.2%+6.8%+7.1%+21.6%+11.0%+10.1%
Depreciation15.9815.1314.3514.7815.2014.9115.5613.36
Interest0.840.831.551.121.151.171.190.95
Profit before tax65.4117514036.3938.0916053.3151.17
Tax16.3542.2136.968.089.7238.4214.6314.14
Net profit49.0613210328.3128.3712138.6837.03
EPS (₹)3.018.146.351.741.757.452.382.28
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,1262,0701,9161,7771,5191,3251,331
Revenue growth+2.7%+8.0%+7.8%+17.0%+14.6%-0.4%-
EBITDA331320338255247324284
EBITDA margin+15.6%+15.5%+17.7%+14.3%+16.3%+24.5%+21.3%
Profit before tax378368398266285380325
Net profit272261291197214275242
Net profit margin+12.8%+12.6%+15.2%+11.1%+14.1%+20.8%+18.2%
EPS (₹)17.5616.8118.8712.1113.0117.4514.43
Balance sheet
Total assets2,5372,3442,1482,0261,9801,7371,557
Net worth2,4932,2872,0971,9811,9491,7221,542
Total debt15.4721.0620.2727.6731.4314.0415.08
Cash & bank38.7840.9721.6520.8032.0626.8628.96
Net working capital287237305263224205182
Cash flow
Cash from operations200310221165162210239
Cash from investing(109)(199)(17.75)3.73(147)(84.15)(84.89)
Cash from financing(93.15)(92.10)(202)(180)(9.70)(126)(142)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue553655564458462642482459
Revenue growth (YoY)+19.7%+2.0%+17.1%-0.2%-8.6%+2.9%--
Other income18.6247.3447.1722.0720.9135.5931.4318.64
Total expenses491512453429427501429413
EBITDA61.6914311228.8234.9014152.8245.94
EBITDA margin+11.2%+21.8%+19.8%+6.3%+7.6%+22.0%+11.0%+10.0%
Depreciation15.9515.0914.3114.7515.1714.8715.5313.32
Interest0.830.821.501.121.151.161.180.94
Profit before tax63.5317414335.0239.4916167.5450.32
Tax15.8442.2535.897.8310.0138.6919.3313.87

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue572668585465473648492464
Revenue growth (YoY)+21.0%+3.0%+18.9%+0.1%-7.9%+1.6%--
Other income17.9447.6649.8920.8020.6335.5016.0818.83
EBITDA64.2914310631.4933.8114053.9846.65
EBITDA margin+11.2%+21.4%+18.2%+6.8%+7.1%+21.6%+11.0%+10.1%
Depreciation15.9815.1314.3514.7815.2014.9115.5613.36
Interest0.840.831.551.121.151.171.190.95
Profit before tax65.4117514036.3938.0916053.3151.17
Tax16.3542.2136.968.089.7238.4214.6314.14
Net profit49.0613210328.3128.3712138.6837.03
EPS (₹)3.018.146.351.741.757.452.382.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1712,1081,9431,7841,5281,3331,344
Revenue growth+3.0%+8.5%+8.9%+16.7%+14.6%-0.8%-
Other income11490.6610249.8676.0997.0468.90
Total expenses1,8461,7831,6041,5331,2741,0011,052
Employee cost483482413391343296277
EBITDA325325339251254332292
EBITDA margin+15.0%+15.4%+17.4%+14.1%+16.6%+24.9%+21.7%
Depreciation59.2453.7339.9238.9437.3037.8137.46
Interest4.994.514.034.093.093.433.42
Profit before tax375357396258289388320
Tax93.1890.4391.1663.9773.2386.5280.07
Net profit268254289190211284236
Net profit margin+12.3%+12.0%+14.9%+10.6%+13.8%+21.3%+17.5%
EPS (₹)17.2916.3918.7511.7012.8217.8514.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.2816.2816.2816.5916.8816.8817.10
Reserves & surplus2,4692,2652,0811,9651,9401,7171,530
Shareholders' funds (net worth)2,4852,2812,0971,9821,9571,7341,547
Minority interest0.000.000.00(0.64)(0.43)(0.17)0.00
Secured loans0.000.000.000.000.000.000.00
Unsecured loans15.4721.1720.5228.3232.2014.5415.08
Total debt15.4721.1720.5228.3232.2014.5415.08
Total liabilities2,5292,3382,1482,0281,9891,7491,563
Assets
Gross block1,3741,180987973947898845
Net block999852680699705689674
Capital work in progress96.4913726119810519.2123.85
Investments1,0481,028843806886790665
Inventories355375389329305215210
Sundry debtors15210911712382.17111124
Cash & bank balances50.0052.7726.2924.9438.6631.5832.32
Loans & advances10367.4283.9093.4973.8951.8758.87
Total current assets660604616570499409425
Total current liabilities359353303304265196241
Net working capital301251314266234212184
Total assets2,5292,3382,1482,0281,9891,7491,563
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash51.4725.4223.8937.7330.4329.8819.92
Net cash from operating activities200318221155162207250
Net cash from investing activities(110)(199)(17.08)11.20(145)(77.18)(98.42)
Net cash from financing activities(93.33)(92.12)(202)(180)(9.84)(129)(142)
Net change in cash(2.79)26.051.53(13.84)7.290.559.96
Closing cash50.0052.7726.2924.9438.6631.5832.32
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.0%+8.5%+8.9%+16.7%+14.6%-0.8%-
EBITDA growth+0.2%-4.1%+34.9%-1.1%-23.6%+13.7%-
PBT growth+4.9%-9.9%+53.7%-10.9%-25.4%+21.2%+35.2%
Net income growth+5.5%-12.2%+52.3%-10.2%-25.5%+20.4%-
Revenue CAGR (3Y)+6.8%+11.3%+13.4%+9.9%+11.9%+7.4%+9.9%
EBITDA CAGR (3Y)+9.0%+8.6%+0.7%-4.9%+3.6%+13.6%+7.1%
Profitability & leverage
Net income margin+13.0%+12.7%+15.7%+10.9%+14.2%+22.6%+17.9%
Return on capital employed+15.6%+16.1%+19.2%+13.0%+15.7%+23.6%+21.5%
Return on net worth+11.8%+12.2%+15.0%+9.8%+11.7%+18.4%+16.0%
Debt / equity0.010.010.010.020.010.010.01
Long-term debt / equity0.000.010.010.010.010.010.00
Interest cover1.881.661.351.931.431.171.34
Efficiency & per share
Fixed asset turnover1.701.951.981.861.661.531.62
Inventory turnover5.955.525.425.635.886.287.01
Debtors turnover16.6618.6416.1917.4215.8611.3812.72
EPS (₹)17.2916.3918.7511.7012.8217.8514.03
Dividend per share (₹)5.005.000.000.000.000.000.80
Book value per share (₹)152.64140.11128.81119.47115.92102.7390.51
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue553655564458462642482459
Revenue growth (YoY)+19.7%+2.0%+17.1%-0.2%-8.6%+2.9%--
Other income18.6247.3447.1722.0720.9135.5931.4318.64
Total expenses491512453429427501429413
EBITDA61.6914311228.8234.9014152.8245.94
EBITDA margin+11.2%+21.8%+19.8%+6.3%+7.6%+22.0%+11.0%+10.0%
Depreciation15.9515.0914.3114.7515.1714.8715.5313.32
Interest0.830.821.501.121.151.161.180.94
Profit before tax63.5317414335.0239.4916167.5450.32
Tax15.8442.2535.897.8310.0138.6919.3313.87
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,1262,0701,9161,7771,5191,3251,331
Revenue growth+2.7%+8.0%+7.8%+17.0%+14.6%-0.4%-
Other income11110610353.9178.7397.1582.66
Total expenses1,7951,7501,5781,5221,2721,0011,048
Employee cost476477409387340294276
EBITDA331320338255247324284
EBITDA margin+15.6%+15.5%+17.7%+14.3%+16.3%+24.5%+21.3%
Depreciation59.1053.6139.7338.7637.0837.6237.36
Interest4.924.494.004.043.053.403.41
Profit before tax378368398266285380325
Tax92.4494.0590.7864.7265.8285.9678.68
Net profit272261291197214275242
Net profit margin+12.8%+12.6%+15.2%+11.1%+14.1%+20.8%+18.2%
EPS (₹)17.5616.8118.8712.1113.0117.4514.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.2816.2816.2816.5916.8816.8817.10
Reserves & surplus2,4762,2712,0811,9641,9321,7051,525
Shareholders' funds (net worth)2,4932,2872,0971,9811,9491,7221,542
Secured loans0.000.000.000.000.000.000.00
Unsecured loans15.4721.0620.2727.6731.4314.0415.08
Total debt15.4721.0620.2727.6731.4314.0415.08
Total liabilities2,5372,3442,1482,0261,9801,7371,557
Assets
Gross block1,3691,176986972942891841
Net block994848676695701685670
Capital work in progress96.4913626119810419.2123.85
Investments1,0701,050850806886790665
Inventories344368383323304213209
Sundry debtors14210411512179.71108124
Cash & bank balances38.7840.9721.6520.8032.0626.8628.96
Loans & advances11270.8584.8210172.4251.6358.42
Total current assets637583605566488400421
Total current liabilities349346300303264195239
Net working capital287237305263224205182
Total assets2,5372,3442,1482,0261,9801,7371,557
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash39.6720.7719.7531.1325.7226.5214.36
Net cash from operating activities200310221165162210239
Net cash from investing activities(109)(199)(17.75)3.73(147)(84.15)(84.89)
Net cash from financing activities(93.15)(92.10)(202)(180)(9.70)(126)(142)
Net change in cash(2.21)18.901.02(11.38)5.41(0.80)12.16
Closing cash38.7840.9721.6520.8032.0626.8628.96
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.7%+8.0%+7.8%+17.0%+14.6%-0.4%-
EBITDA growth+3.5%-5.4%+33.0%+3.1%-23.9%+14.4%-
PBT growth+2.9%-7.6%+49.8%-6.9%-25.0%+16.9%+37.7%
Net income growth+4.5%-10.4%+47.9%-8.3%-22.1%+13.5%-
Revenue CAGR (3Y)+6.2%+10.9%+13.1%+10.1%+12.2%+7.7%+9.7%
EBITDA CAGR (3Y)+9.2%+9.1%+1.4%-3.5%+4.5%+14.0%+6.3%
Profitability & leverage
Net income margin+13.5%+13.2%+16.0%+11.3%+14.5%+22.2%+18.5%
Return on capital employed+15.7%+16.6%+19.3%+13.5%+15.5%+23.3%+22.0%
Return on net worth+12.0%+12.5%+15.1%+10.2%+12.0%+18.0%+16.6%
Debt / equity0.010.010.010.020.010.010.01
Long-term debt / equity0.000.010.010.010.010.010.00
Interest cover1.811.681.341.871.451.191.38
Efficiency & per share
Fixed asset turnover1.671.921.961.861.661.531.61
Inventory turnover5.985.515.425.675.886.276.97
Debtors turnover17.2718.9516.2517.6916.2011.4312.82
EPS (₹)17.5616.8118.8712.1113.0117.4514.43
Dividend per share (₹)5.005.000.000.000.000.000.80
Book value per share (₹)153.10140.48128.81119.39115.44102.0290.18

To see the full year-wise statements and ratios of FDC Limited, buy the company report.

Board of directors of FDC Limited

FDC has 10 current directors and 15 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Mahesh Chandru BijlaniDirector10 May 20197 Years 5 MonthsCurrent
Vijay Maniar
Also directs: Transpek Industry Limited, India Infradebt Limited
Director04 Aug 20224 Years 3 MonthsCurrent
Nandan Mohan Chandavarkar
Also directs: Bombay Merchants Cup LLP, True North Sailing Association
Whole-Time Director30 Sep 199333 Years 1 MonthsCurrent
Mohan Chandavarkar AnandManaging Director01 Apr 200917 Years 7 MonthsCurrent
Nomita Ramdas Chandavarkar
Also directs: Akhil Farma Limited, DSS Out Sourcing Solutions Private Limited
Director02 Jun 201412 Years 5 MonthsCurrent
Ashok Anand Chandavarkar
Also directs: Rene Advisors LLP, Virgo Advisors Private Limited, Leo Advisors Private Limited
Whole-Time Director01 Mar 201115 Years 8 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

FDC Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Pfizer Limited₹2,453.6 Cr (FY 2025)3.0%Mumbai, Maharashtra, India
Marksans Pharma Limited₹2,227.83 Cr (FY 2024)17.0%Mumbai, Maharashtra, India
FDC Limitedthis company₹2,170.93 Cr (FY 2026)₹267.72 Cr12.3%3.0%6,548Mumbai, Maharashtra, India
Unichem Laboratories Limited₹2,146.29 Cr (FY 2025)18.0%Mumbai, Maharashtra, India
Caplin Point Laboratories Limited₹2,033.9 Cr (FY 2025)15.0%Chennai, Tamil Nadu, India
Astrazeneca Pharma India Limited₹1,756.92 Cr (FY 2025)32.0%Bangalore, Karnataka, India

To see the full peer comparison of FDC Limited, buy the company report.

Auditor

FDC Limited is audited by BSR & CO LLP for the financial year 2025.

Auditor firmFinancial yearFirm registration number
BSR & CO LLPFY 2025101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 69.70%, foreign institutional investors hold 1.40%, domestic institutional investors hold 6.30% and retail and other public shareholders hold 22.60%.

Promoters: 69.70%DII (Domestic Institutional): 6.30%FII (Foreign Institutional): 1.40%Retail & Others: 22.60%
Sep 2026
QUARTER
69.70% Promoters
6.30% DII (Domestic Institutional)
1.40% FII (Foreign Institutional)
22.60% Retail & Others
Promoter holding - history
Now 69.70% · Sep 2026High 69.70% · Dec 2025Low 69.70% · Dec 2025
68%68.8%69.5%70.3%71%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 69.70%Mar 2026: 69.70%Jun 2026: 69.70%Sep 2026: 69.70%69.70%69.70%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters69.70%69.70%69.70%69.70%
Public30.30%30.30%30.30%30.30%

Charges & borrowings

Open charges
None
Satisfied charges
₹7.43 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹6.50 Cr
Syndicate Bank₹0.59 Cr
The Saraswat Co-Operative Bank Limited₹0.20 Cr
The Sarasawat Co-Operative Bank Ltd.₹0.14 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
26 Apr 201010220462Hdfc Bank Limited₹6.5 CrSatisfied
17 May 199690229077The Saraswat Co-Operative Bank Limited₹13.1 LakhSatisfied
23 Mar 199290228520Syndicate Bank₹3 LakhSatisfied
08 May 198690227876Syndicate Bank₹10.5 LakhSatisfied
26 Apr 198390227665Syndicate Bank₹10 LakhSatisfied

To see the full charge records of FDC Limited, buy the company report.

Total charge records: 17 View all charges

Deals & funding

FDC Limited has 29 deals on record (18 secondary share transfers, 9 market trades, 2 buybacks); the latest was in September 2024.

Total deals
29
Secondary share transfers
18
Market trades
9
Buybacks
2

Deals on record (5 of 29)

WhenDealAmountParties
Sep 2024Market trade₹67.96 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Aug 2017Secondary share transferUndisclosedBuyer: Pinebridge Investments, Virgo Advisors Private Limited , Leo Advisors Private Limited
Seller: Others - FDC Limited, 3 individuals
Mar 2016Secondary share transferUndisclosedBuyer: Pinebridge Investments, Soven Trading and Investmment Co Pvt Ltd , Transgene Trading and Investment Co Pvt Ltd
Seller: Fidelity Low-Priced Stock Fund, Reliance Small Cap Fund, Others - FDC Limited, an individual
Aug 2014Market trade₹112.02 CrBuyer: Sudipta Trading And Investment Company Pvt Ltd, Transgene Trading and Investment Co Pvt Ltd
Seller: an individual
Aug 2014Market trade₹129.51 CrBuyer: Sudipta Trading And Investment Company Pvt Ltd, Transgene Trading and Investment Co Pvt Ltd , Soven Trading And Investment Company Pvt Ltd
Seller: 4 individuals

To see the full deal history of FDC Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

FDC Limited has 16 MSME Form 1 returns on record between 2017 and 2022, listing 1,308 overdue payments to 330 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 330)

SupplierAmount dueDue sinceReported on
Synokem Pharmaceuticals Limited
Kalapi Printing Press
Nimit Kraftpack Industries
Shah Print Pack
Laxmi Pharma Pack

To see the full MSME payment records of FDC Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

FDC Limited has a workforce of 6,548 employees on its EPFO records as of Oct 10, 2025, across 5 active EPFO establishments.

Employee count
6,548
Active EPFO establishments
5
Employee growth
3.39%

GST

FDC has 2 GST registrations on record, and all of them have been cancelled or are inactive. Only active GST numbers are listed on this page.

Total GSTINs
2
Cancelled / inactive
2

To see the full GST registrations and return filing status of FDC Limited, buy the company report.

Recent activity

FDC Limited has 29 board changes on record since 1977: 19 appointments and 10 cessations. The latest: Kishore Mukund Saletore was appointed as Additional Director on 01 Apr 2026.

Appointed
Kishore Mukund Saletore was appointed as Additional Director.
Filing
Fdc Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Fdc Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Ceased
Swati Sandesh Mayekar ceased to be Director.
Appointed
Charuta Nityanath Mandke was appointed as Director.
Ceased
Melarkode Ganesan Parameswaran ceased to be Director.
Ceased
Usha Athreya Chandrasekhar ceased to be Director.
Appointed
Vijay Nautamlal Bhatt was appointed as Director.
Appointed
Vijay Maniar was appointed as Director.
Appointed
Mahesh Chandru Bijlani was appointed as Director.
Appointed
Melarkode Ganesan Parameswaran was appointed as Director.
Appointed
Usha Athreya Chandrasekhar was appointed as Director.

56 earlier events are in the company report.

News

FDC: Q2 REVENUE 5.72B RUPEES VS 4.73B (YOY)
27 Oct 2026 · Exchange Update
FDC: Q2 CONS NET PROFIT 491M RUPEES VS 284M (YOY)
27 Oct 2026 · Exchange Update
FDC: Q2 EBITDA 642M RUPEES VS 338M (YOY); Q2 EBITDA MARGIN 11.24% VS 7.15% (YOY)
27 Oct 2026 · Exchange Update
FDC: Company's Board To Review Proposal For Buying Back Fully Paid Equity Shares Through Tender Offer
21 Oct 2026 · Exchange Update

Frequently asked questions

FDC is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 September 1940 (86+ years old) and is registered under CIN L24239MH1940PLC003176. Listed on BSE: 531599 and NSE: FDC.

FDC reported revenue of ₹2,170.93 Cr for FY 2025-26 (up 3% YoY) based on consolidated financials.

FDC has 10 current directors:

The latest financial statements of FDC on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.

No. FDC has 2 GST registrations on record and all of them are cancelled or inactive.

The CIN (Corporate Identification Number) of FDC is L24239MH1940PLC003176. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. FDC is a listed company as per MCA records. Its shares are listed on both BSE (code: 531599) and NSE (symbol: FDC).

FDC has 333 court cases on record: 200 filed by the company and 133 filed against it. 58 are pending. Most are in the high courts.

FDC was incorporated on 23 September 1940, making it 86+ years old. It is registered with the Registrar of Companies, Mumbai.

FDC has 29 deals on record (18 secondary share transfers, 9 market trades, 2 buybacks); the latest was in September 2024.

The peers of FDC by revenue are Pfizer Limited, Marksans Pharma Limited, Unichem Laboratories Limited, Caplin Point Laboratories Limited, Astrazeneca Pharma India Limited, all in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Kishore Mukund Saletore was appointed as Additional Director on 01 Apr 2026. Swati Sandesh Mayekar ceased to be Director on 06 Sep 2024. Charuta Nityanath Mandke was appointed as Director on 07 Aug 2024. FDC has 29 board changes on record in total.